Camurs gets FDA’s green light to kick off phase 3 testing of treatment of acromegaly and neuroendocrine tumors
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Read moreCamurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Read more